177 related articles for article (PubMed ID: 21999732)
1. Nitric oxide modulation of the basal ganglia circuitry: therapeutic implication for Parkinson's disease and other motor disorders.
Pierucci M; Galati S; Valentino M; Di Matteo V; Benigno A; Pitruzzella A; Muscat R; Di Giovanni G
CNS Neurol Disord Drug Targets; 2011 Nov; 10(7):777-91. PubMed ID: 21999732
[TBL] [Abstract][Full Text] [Related]
2. Serotonin modulation of the basal ganglia circuitry: therapeutic implication for Parkinson's disease and other motor disorders.
Di Matteo V; Pierucci M; Esposito E; Crescimanno G; Benigno A; Di Giovanni G
Prog Brain Res; 2008; 172():423-63. PubMed ID: 18772045
[TBL] [Abstract][Full Text] [Related]
3. Serotonin involvement in the basal ganglia pathophysiology: could the 5-HT2C receptor be a new target for therapeutic strategies?
Di Giovanni G; Di Matteo V; Pierucci M; Benigno A; Esposito E
Curr Med Chem; 2006; 13(25):3069-81. PubMed ID: 17073648
[TBL] [Abstract][Full Text] [Related]
4. Functional organization of the basal ganglia: therapeutic implications for Parkinson's disease.
Obeso JA; Rodríguez-Oroz MC; Benitez-Temino B; Blesa FJ; Guridi J; Marin C; Rodriguez M
Mov Disord; 2008; 23 Suppl 3():S548-59. PubMed ID: 18781672
[TBL] [Abstract][Full Text] [Related]
5. Chapter 33: the history of movement disorders.
Lanska DJ
Handb Clin Neurol; 2010; 95():501-46. PubMed ID: 19892136
[TBL] [Abstract][Full Text] [Related]
6. Interaction between the 5-HT system and the basal ganglia: functional implication and therapeutic perspective in Parkinson's disease.
Miguelez C; Morera-Herreras T; Torrecilla M; Ruiz-Ortega JA; Ugedo L
Front Neural Circuits; 2014; 8():21. PubMed ID: 24672433
[TBL] [Abstract][Full Text] [Related]
7. The functions of the basal ganglia and the paradox of stereotaxic surgery in Parkinson's disease.
Marsden CD; Obeso JA
Brain; 1994 Aug; 117 ( Pt 4)():877-97. PubMed ID: 7922472
[TBL] [Abstract][Full Text] [Related]
8. Distribution and roles of metabotropic glutamate receptors in the basal ganglia motor circuit: implications for treatment of Parkinson's disease and related disorders.
Rouse ST; Marino MJ; Bradley SR; Awad H; Wittmann M; Conn PJ
Pharmacol Ther; 2000 Dec; 88(3):427-35. PubMed ID: 11337032
[TBL] [Abstract][Full Text] [Related]
9. The endocannabinoid system as a target for the treatment of motor dysfunction.
Fernández-Ruiz J
Br J Pharmacol; 2009 Apr; 156(7):1029-40. PubMed ID: 19220290
[TBL] [Abstract][Full Text] [Related]
10. Role of nitric oxide in motor control: implications for Parkinson's disease pathophysiology and treatment.
Del-Bel E; Padovan-Neto FE; Raisman-Vozari R; Lazzarini M
Curr Pharm Des; 2011; 17(5):471-88. PubMed ID: 21375483
[TBL] [Abstract][Full Text] [Related]
11. Lack of depotentiation at basal ganglia output neurons in PD patients with levodopa-induced dyskinesia.
Prescott IA; Liu LD; Dostrovsky JO; Hodaie M; Lozano AM; Hutchison WD
Neurobiol Dis; 2014 Nov; 71():24-33. PubMed ID: 25116960
[TBL] [Abstract][Full Text] [Related]
12. Anatomy of the dopamine system in the basal ganglia.
Smith Y; Kieval JZ
Trends Neurosci; 2000 Oct; 23(10 Suppl):S28-33. PubMed ID: 11052217
[TBL] [Abstract][Full Text] [Related]
13. Balancing the basal ganglia circuitry: a possible new role for dopamine D2 receptors in health and disease.
Cazorla M; Kang UJ; Kellendonk C
Mov Disord; 2015 Jun; 30(7):895-903. PubMed ID: 26018615
[TBL] [Abstract][Full Text] [Related]
14. Current Understanding of PDE10A in the Modulation of Basal Ganglia Circuitry.
Schülke JP; Brandon NJ
Adv Neurobiol; 2017; 17():15-43. PubMed ID: 28956328
[TBL] [Abstract][Full Text] [Related]
15. Roles of the M
Moehle MS; Conn PJ
Mov Disord; 2019 Aug; 34(8):1089-1099. PubMed ID: 31211471
[TBL] [Abstract][Full Text] [Related]
16. Substantia nigra control of basal ganglia nuclei.
Guatteo E; Cucchiaroni ML; Mercuri NB
J Neural Transm Suppl; 2009; (73):91-101. PubMed ID: 20411770
[TBL] [Abstract][Full Text] [Related]
17. Basal ganglia, movement disorders and deep brain stimulation: advances made through non-human primate research.
Wichmann T; Bergman H; DeLong MR
J Neural Transm (Vienna); 2018 Mar; 125(3):419-430. PubMed ID: 28601961
[TBL] [Abstract][Full Text] [Related]
18. Behavioural disorders induced by external globus pallidus dysfunction in primates II. Anatomical study.
François C; Grabli D; McCairn K; Jan C; Karachi C; Hirsch EC; Féger J; Tremblay L
Brain; 2004 Sep; 127(Pt 9):2055-70. PubMed ID: 15292054
[TBL] [Abstract][Full Text] [Related]
19. The basal ganglia in Parkinson's disease: current concepts and unexplained observations.
Obeso JA; Marin C; Rodriguez-Oroz C; Blesa J; Benitez-Temiño B; Mena-Segovia J; Rodríguez M; Olanow CW
Ann Neurol; 2008 Dec; 64 Suppl 2():S30-46. PubMed ID: 19127584
[TBL] [Abstract][Full Text] [Related]
20. The pharmacology of tardive dyskinesias.
Klawans HL
Am J Psychiatry; 1973 Jan; 130(1):82-6. PubMed ID: 4264755
[No Abstract] [Full Text] [Related]
[Next] [New Search]
